Cellier, C, Bouma, G, van Gils, T, Khater, S, Malamut, G, Crespo, L, Collin, P, Green, P H R, Crowe, S E, Tsuji, W, Butz, E, Cerf-Bensussan, N, Macintyre, E, Parnes, J R, Leon, F, Hermine, O, Mulder, C J, Jabri, B, Murray, J, DiMarino, A, Kelly, C P, Byrnes, V, Sanders, D, Lundin, K E A, Schumann, M, Bontkes, H, Meresse, B, Roy Ariño, G, Bhagat, G, Viiri, K, Rounioja, S, Bui, J, Perez Maseda, R, García-Hoz, C, Trinquand, A, Vlad, G, Hadjivassiliou, M, Azizi, M, Blanchard, A, Llewellyn, B, Palmer, A & Raymond, R 2019, ' Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study ', The Lancet Gastroenterology and Hepatology, vol. 4, no. 12, pp. 960-970 . https://doi.org/10.1016/S2468-1253(19)30265-1 The Lancet Gastroenterology and Hepatology The Lancet Gastroenterology and Hepatology, Elsevier, 2019, 4, pp.960-970. ⟨10.1016/S2468-1253(19)30265-1⟩ The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology, 2019, 4, pp.960-970. ⟨10.1016/S2468-1253(19)30265-1⟩ The Lancet Gastroenterology and Hepatology, 4(12), 960-970. Elsevier Ltd